- LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
- LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
- LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
- LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
- LumiraDx Reports Second Quarter 2023 Results
- LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
- LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
- LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
- LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
More ▼
Key statistics
On Tuesday, LumiraDx Ltd (LMDXF:PKL) closed at 0.0175, 150.00% above the 52 week low of 0.007 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.018 |
---|---|
High | 0.0223 |
Low | 0.0131 |
Bid | -- |
Offer | -- |
Previous close | 0.0182 |
Average volume | 606.35k |
---|---|
Shares outstanding | 164.32m |
Free float | 162.68m |
P/E (TTM) | -- |
Market cap | 2.99m USD |
EPS (TTM) | -1.08 USD |
Data delayed at least 15 minutes, as of May 21 2024 20:58 BST.
More ▼